Back to top

crispr: Archive

Sundeep Ganoria

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?

CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.

REGNPositive Net Change VRTXNegative Net Change NTLAPositive Net Change CRSPNegative Net Change

Sundeep Ganoria

Can Casgevy Deliver a Turnaround for CRISPR Therapeutics?

CRSP bets on Casgevy to drive growth, but its extremely high price tag and slow rollout test investor patience in a crowded field.

NVSNegative Net Change BMYPositive Net Change VRTXNegative Net Change BEAMPositive Net Change CRSPNegative Net Change